Contineum Therapeutics, Inc.
No enriched coverage for $CTNM in the last 7 days.
No SEC Form 4 filings for $CTNM in the last 30 days.
See all $CTNM insider activity →Baird downgraded Contineum Therapeutics (CTNM) to Neutral, lowering its price target to $14 from $19. The stock is near its 52-week low after a trial showed mixed results. Analysts remain divided, with Stifel maintaining a Buy rating and a $28 target, while Goldman Sachs initiated coverage with an Early-Stage Biotech rating.
Contineum Therapeutics (CTNM) fell 25% after Bristol Myers (BMY) reported mixed Phase 3 trial results for admilparant in IPF. The 60mg dose met its primary endpoint, but the 120mg dose did not. Stifel maintains a Buy rating on CTNM, citing clinical validation for the LPA1 mechanism and potential upside.
Contineum Therapeutics (CTNM) shares rose 27% in pre-market trading after Bristol Myers Squibb's Phase 3 trial for admilparant in idiopathic pulmonary fibrosis met its primary endpoint. Contineum's PIPE-791 targets the same biological pathway. CTNM was indicated at $16.99, up from $13.38. Stifel previously noted the trial's importance for Contineum's valuation.
Recent CTNM coverage spans technology, financial news and market movers.
The downgrade and mixed trial results are likely to push the stock lower.
CTNM likely faces short-term selling pressure but retains upside potential as analysts reiterate a Buy rating.
Positive trial data for a peer drug validates Contineum’s pipeline, likely driving further buying pressure.
Negative trial data likely pressures CTNM stock lower.
Analyst initiation and trial outcome may pressure the stock lower in the short term.
AlphAI scores every news story that mentions CTNM with an AI model for sentiment and relevance, and aggregates insider trades from Contineum Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Baird downgraded Contineum Therapeutics (CTNM) to Neutral, lowering its price target to $14 from $19. The stock is near its 52-week low after a trial showed mixed results. Analysts remain divided, with Stifel maintaining a Buy rating and a $28 target, while Goldman Sachs initiated coverage with an Early-Stage Biotech rating.
2 min readContineum Therapeutics (CTNM) fell 25% after Bristol Myers (BMY) reported mixed Phase 3 trial results for admilparant in IPF. The 60mg dose met its primary endpoint, but the 120mg dose did not. Stifel maintains a Buy rating on CTNM, citing clinical validation for the LPA1 mechanism and potential upside.
2 min readContineum Therapeutics (CTNM) shares rose 27% in pre-market trading after Bristol Myers Squibb's Phase 3 trial for admilparant in idiopathic pulmonary fibrosis met its primary endpoint. Contineum's PIPE-791 targets the same biological pathway. CTNM was indicated at $16.99, up from $13.38. Stifel previously noted the trial's importance for Contineum's valuation.
1 min readContineum Therapeutics (CTNM) and Johnson & Johnson (JNJ) reported that their depression drug, JNJ-5120/PIPE-307, failed to meet the primary endpoint in a Phase 2 trial. The drug showed no new safety issues but did not demonstrate the required efficacy in treating major depressive disorder. JNJ is analyzing additional data to determine the next steps for the program.
4 min readGoldman Sachs initiated coverage on Contineum Therapeutics (NASDAQ:CTNM) with an Early-Stage Biotech rating. The stock trades at $12.51, down 5.3% in a week. The company is developing oral therapies for inflammatory and fibrotic conditions. Its lead candidate, PIPE-791, is in a Phase 2 trial for idiopathic pulmonary fibrosis. Despite a recent trial failure, Stifel maintains a Buy rating with a $28 price target.
2 min readRBC Capital's Brian Abrahams maintained a Buy rating and $21.00 price target for Contineum Therapeutics (CTNM). The analyst has a 12.1% average return and 51.90% success rate. The Street's consensus is Strong Buy with a $22.14 average target. CTNM reported a $15.15M quarterly net loss, improving from last year's $16.04M.
1 min readContineum Therapeutics (CTNM) shares fell 10% after-hours after J&J's (JNJ) mid-stage trial of PIPE-307, licensed from CTNM, failed to meet its primary goal in treating major depressive disorder. This is the second mid-stage setback for the molecule in under a year. JNJ is reviewing exploratory measures and has not decided on further development. CTNM has $236.6 million in cash, expected to last through mid-2029.
2 min readContineum Therapeutics (CTNM) shares dropped 8% after reporting its phase 2 trial for JNJ-5120/PIPE-307 in major depressive disorder failed to meet its primary endpoint. The drug was well-tolerated, and Johnson & Johnson is reviewing the data to determine next steps. Contineum Therapeutics is a clinical-stage biopharmaceutical company.
1 min readContineum Therapeutics (CTNM) shares rose from lows to a 52-week high. The company's lead drug, PIPE-791, is in a Phase 2 trial for idiopathic pulmonary fibrosis. CTNM's stock has climbed 125% since February 2025, with key catalysts including positive trial results and upcoming conferences. The company also collaborates with Johnson & Johnson on PIPE-307 for depression.
2 min readContineum Therapeutics, Inc. (CTNM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS SECOND-QUARTER 2026 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES SAN DIEGO – July 30, 2026 – Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering
6 min read
